Pharmascience, a Canada-based generic pharmaceutical company, has acquired corporate venturing-backed local peer Aegera Therapeutics for an undisclosed amount.
In 2006 Aegera had previously raised more than C$44m ($45m) in the three rounds from 2002 from a consortium including Genechem, a venture capital firm started by BioChem Pharma (now Shire Pharmaceuticals), VenGrowth, GrowthWorks, Business Development Bank of Canada, Desjardins Venture Capital, Multiple Capital and Solidarity Fund (QFL), Fondaction CSN, T2C2/Bio 2000 and Innovatech.